Home / Features / Intel Corporation (NASDAQ:INTC) Hopes Acquisition Would Push Wearables Firm To The Next Level- Endologix (NASDAQ:ELGX)

Intel Corporation (NASDAQ:INTC) Hopes Acquisition Would Push Wearables Firm To The Next Level- Endologix (NASDAQ:ELGX)

Shares of Intel Corporation (NASDAQ:INTC) [Trend Analysis] swings enthusiastically in regular trading session, it a loss of -0.20% to close at $34.95. When Intel (INTC) bought Basis back in 2014, there were hopes acquisition would push the wearables firm to the next level. Sadly, things didn’t go that way the firm’s first Intel-backed product had a tendency to catch fire, and was subsequently pulled from the market earlier this year.

Now, any hope for a bounce back has been all but extinguished: according to a report from TechCrunch, Intel’s wearable division is facing massive job cuts. Moving forward to saw long-term intention, the experts calculate Return on Investment of 13.60%. The stock is going forward its fifty-two week low with 29.29% and lagging behind from its 52-week high price with -8.20%. INTC last month stock price volatility remained 1.58%.

Endologix Inc. (NASDAQ:ELGX) [Trend Analysis] knocking active thrust in leading trading session, shares a loss of -1.54% to 7.69 with about 5.15 Million shares have changed hands in this session. Goldberg Law PC reported that it is investigating Endologix Inc. (ELGX) concerning possible infringement of federal securities laws. The examination focuses on whether Endologix and certain of its officers and/or directors violated federal securities laws.

On August 2, 2016, CEO John McDermott stated that Endologix would seek authorization of the original version of the Nellix system that was used in the Nellix examinational device exemption clinical trial, the EVAS FORWARD-IDE Study, given since Endologix had the needed clinical data. On November 16, 2016, Endologix reported that the U.S. Food & Drug Administration requested two-year follow-up data on patients enrolled in the EVAS-FORWARD-IDE study to assess Nellix. When this news was reported, shares of Endologix fell in value. The stock is going forward its fifty-two week low with 23.63% and lagging behind from its 52-week high price with -46.97%.

Same, the positive performance for the quarter recorded as -35.65% and for the year was -23.48%, while the YTD performance remained at -22.32%. ELGX has Average True Range for 14 days of 0.73.

 

About Blake Escott

Blake Escott holds junior writer position in SWR. Before joining Streetwise Report, he was a freelance content Writer. He has high-level copywriting experience and particularly experienced in proofreading and editing. He covers news about different companies including all US market sectors. Interests: Commodities, Energy stocks, Sector-wise Stocks analysis, Utilities

Check Also

x

United States Steel Corporation (NYSE:X) Could Be Looking At Restoring Up To 10K Jobs In U.S.

United States Steel Corporation (NYSE:X) [Trend Analysis] climbed reacts as active mover, shares an increase 4.28% …

Leave a Reply

Your email address will not be published. Required fields are marked *